Page last updated: 2024-08-24

naxagolide and Atherosclerotic Parkinsonism

naxagolide has been researched along with Atherosclerotic Parkinsonism in 17 studies

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19907 (41.18)18.7374
1990's10 (58.82)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA1
Guillén, J; Laguna, J; Luquin, MR; Martínez-Lage, JM; Martínez-Vila, E1
Herrero, MT; Laguna, J; Luquin, MR; Obeso, JA1
Laguna, J; Luquin, MR; Obeso, JA1
Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ1
Bédard, PJ; Gomez-Mancilla, B1
Alexander, GM; Brainard, DL; Gordon, SW; Grothusen, JR; Hichens, M; Schwartzman, RJ1
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S1
de Yébenes, JG; Fahn, S; Goodman, R; Jamrosik, Z; Pezzoli, G; Popalski, S1
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ1
Bondi, JV; Hichens, M; Iversen, SD; Jennings, CA; Loper, AE; Rupniak, NM; Stahl, SM; Tye, SJ1
Bondi, JV; Hand, E; Hichens, M; Iversen, SD; Jennings, CA; Loper, AE; Rupniak, NM; Stahl, SM; Tye, SJ1
Jenner, P; Marsden, CD; Nomoto, M; Stahl, S1
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM1
Gordon, J; Herbster, G; Koller, W1
de Yebenes, JG; Fahn, S; Jackson-Lewis, V; Mena, MA1
Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM1

Reviews

1 review(s) available for naxagolide and Atherosclerotic Parkinsonism

ArticleYear
Neurotoxin-related research: from the laboratory to the clinic.
    Annals of the New York Academy of Sciences, 1992, May-11, Volume: 648

    Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri

1992

Other Studies

16 other study(ies) available for naxagolide and Atherosclerotic Parkinsonism

ArticleYear
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1994, Volume: 9, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes

1994
Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
    European journal of pharmacology, 1994, Mar-03, Volume: 253, Issue:3

    Topics: Animals; Benzazepines; Dopamine Agents; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Female; Indoles; Macaca fascicularis; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2; Sulpiride

1994
Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys.
    Journal of the neurological sciences, 1993, Volume: 114, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Drug Tolerance; Female; Macaca fascicularis; Male; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Psychomotor Performance

1993
Selective D2 receptor stimulation induces dyskinesia in parkinsonian monkeys.
    Annals of neurology, 1992, Volume: 31, Issue:5

    Topics: Animals; Benzazepines; Dopamine Agents; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Movement Disorders; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D2

1992
Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys.
    Experimental neurology, 1992, Volume: 117, Issue:2

    Topics: Animals; Antiparkinson Agents; Dopamine Agents; Female; Indoles; Macaca fascicularis; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenanthridines; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2

1992
Dopamine receptor changes in untreated and (+)-PHNO-treated MPTP parkinsonian primates.
    Brain research, 1991, May-03, Volume: 547, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine

1991
Modulatory role for CCK-B antagonists in Parkinson's disease.
    Clinical neuropharmacology, 1990, Volume: 13, Issue:4

    Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri

1990
Intracerebroventricular infusion of (+)-4-propyl-9-hydroxy-naphthoxacine in monkeys with MPTP-induced akinesia.
    Advances in neurology, 1990, Volume: 53

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Dopamine; Dopamine Agents; Injections, Intraventricular; Macaca fascicularis; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Rats; Receptors, Dopamine

1990
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
    Neurology, 1990, Volume: 40, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri

1990
Therapeutic efficacy of a novel transdermal delivery system for (+)-PHNO in parkinsonian squirrel monkeys.
    Journal of neurology, neurosurgery, and psychiatry, 1989, Volume: 52, Issue:2

    Topics: Administration, Cutaneous; Animals; Oxazines; Parkinson Disease, Secondary; Saimiri

1989
Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
    Neurology, 1989, Volume: 39, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Behavior, Animal; Male; Oxazines; Parkinson Disease, Secondary; Pyridines; Saimiri

1989
Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Callithrix; Dopamine Agents; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Pyridines

1987
Antiparkinsonian activity of a single oral dose of PHNO.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:1

    Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time

1987
PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:3

    Topics: Animals; Corpus Striatum; Dopamine Agents; Dose-Response Relationship, Drug; Injections, Subcutaneous; Male; Oxazines; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior

1987
The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    Movement disorders : official journal of the Movement Disorder Society, 1987, Volume: 2, Issue:4

    Topics: Animals; Brain; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Infusion Pumps; Injections, Intraventricular; Male; Motor Activity; Neural Pathways; Oxazines; Parkinson Disease, Secondary; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Substantia Nigra

1987
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Naunyn-Schmiedeberg's archives of pharmacology, 1988, Volume: 338, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines

1988